Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24704123 | 0.84 | HTT (0.34) | MAPK14KDM4EUSP2ALDH1A1PKM | |
| SCHEMBL22862452 | 0.81 | — | — | |
| SCHEMBL22862438 | 0.77 | ALDH1A1 (0.40) | MAPK14KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL22862777 | 0.76 | KDM4E (0.37) | MAPK14PDE1CKDM4EALDH1A1LMNA | |
| SCHEMBL24704592 | 0.76 | TNIK (0.35) | MAPK14MAPK13MAPK12MAPK11GABRA2 | |
| SCHEMBL22862877 | 0.75 | SIGMAR1 (0.39) | — | |
| SCHEMBL24704416 | 0.71 | SMN1; SMN2 (0.39) | KDM4EALDH1A1PKM | |
| SCHEMBL22862994 | 0.69 | KDM4E (0.37) | MAPK14PDE1CKDM4EALDH1A1MAPT | |
| SCHEMBL22862770 | 0.69 | KDM4E (0.33) | MAPK14PDE1CKDM4EALDH1A1 | |
| SCHEMBL24704121 | 0.68 | CDK9 (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | MAPK14 765/4885MAPK13 1779/4885MAPK12 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.